Mesoblast Limited vs Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.83B), while Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) trades at $8.59 (market cap $9.09B). The key difference: Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) is far larger — about 5× Mesoblast Limited's market cap, and Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) pays a 3.84% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) for 0 Days on average.
| MESO | YMM | |
|---|---|---|
Market Cap | $1.83B | $9.09B |
Volume | 259,445 | 10,124,674 |
Sector | Health | Technology |
52-Week High | $20.96 | $13.30 |
52-Week Low | $13.19 | $7.54 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $1.91B | $5.57B |
Dividend Yield | — | 3.84% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Full Truck Alliance Co. Ltd. operates a digital freight-matching platform in China, connecting shippers with truckers for cargo transport across varying distances and load types.
Read more on YMM →